酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)抑制BCR-ABL融合基因,使慢性粒细胞白血病(chronic myelocytic leukemia,CML)患者能够较长期生存。患者使用TKIs早期出现不良反应都较轻,可自行恢复或者给予对症处理和选择其他TKIs。而TKIs长期的使用的安全性问题国内少有报道,本文通过查阅国内外文献,综述TKIs引起的骨髓、皮肤、胃肠、肝和胰、骨骼肌、肺、液体潴留、心血管方面的不良反应以及其临床对策。 Tyrosine kinase inhibitors (TKIs) inhibit the BCR-ABL fusion gene, allowing patients with chronic myelocytic leukemia (CML) to survive longer. TKIs in patients with early adverse reactions are lighter, can be restored or given symptomatic treatment and select other TKIs. The long-term use of TKIs safety issues rarely reported in China, this article by referring to domestic and foreign literature, review of TKIs caused bone marrow, skin, gastrointestinal, liver and pancreas, skeletal muscle, lung, fluid retention, cardiovascular adverse reactions As well as its clinical strategy.